Beta Drugs Balance Sheet Health
Financial Health criteria checks 6/6
Beta Drugs has a total shareholder equity of ₹1.8B and total debt of ₹190.6M, which brings its debt-to-equity ratio to 10.5%. Its total assets and total liabilities are ₹2.9B and ₹1.1B respectively. Beta Drugs's EBIT is ₹558.1M making its interest coverage ratio 27.2. It has cash and short-term investments of ₹278.9M.
Key information
10.5%
Debt to equity ratio
₹190.60m
Debt
| Interest coverage ratio | 27.2x |
| Cash | ₹278.87m |
| Equity | ₹1.81b |
| Total liabilities | ₹1.14b |
| Total assets | ₹2.95b |
Recent financial health updates
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Financial Position Analysis
Short Term Liabilities: BETA's short term assets (₹2.1B) exceed its short term liabilities (₹972.5M).
Long Term Liabilities: BETA's short term assets (₹2.1B) exceed its long term liabilities (₹164.0M).
Debt to Equity History and Analysis
Debt Level: BETA has more cash than its total debt.
Reducing Debt: BETA's debt to equity ratio has reduced from 32.5% to 10.5% over the past 5 years.
Debt Coverage: BETA's debt is well covered by operating cash flow (132.1%).
Interest Coverage: BETA's interest payments on its debt are well covered by EBIT (27.2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 19:06 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beta Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|